KALA BIO gets Nasdaq $35M MVLS notice, 180‑day cure window

KALA BIO reported it received a Nasdaq deficiency notice for failing to meet the Nasdaq Capital Market’s market value of listed securities requirement.

Rhea-AI Filing Summary

KALA BIO reported it received a Nasdaq deficiency notice for failing to meet the Nasdaq Capital Market’s market value of listed securities requirement. The company’s market value was below $35 million for 30 consecutive business days, triggering noncompliance with Listing Rule 5550(b)(2).

Nasdaq granted a 180‑day cure period until May 11, 2026. Compliance is regained if the market value closes at $35 million or more for at least 10 consecutive business days before the deadline. The filing also notes KALA BIO does not meet the alternative continued listing standards of stockholders’ equity of at least $2.5 million or net income from continuing operations of at least $500,000 in the relevant periods.

If compliance is not restored by the deadline, the company may receive a delisting notice and could appeal to a Nasdaq Listing Qualifications Panel. KALA BIO plans to monitor its market value and may consider options to regain compliance.

Insights

Capital markets compliance analyst

Nasdaq MVLS deficiency adds listing risk; 180-day cure window.

KALA BIO fell below the Nasdaq Capital Market’s market value of listed securities threshold of $35 million for 30 consecutive business days, prompting a deficiency notice. The company has until May 11, 2026 to regain compliance by maintaining at least 10 consecutive business days at or above $35 million.

The filing also states KALA BIO does not meet alternative standards (stockholders’ equity of $2.5 million or net income of $500,000). Absent compliance, Nasdaq may issue a delisting notice; an appeal to a Listing Qualifications Panel is permitted but not assured.

Key items are the market value trajectory relative to the $35 million threshold and any actions the company takes to address listing criteria. Outcomes depend on market value performance within the cure period.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/12/2025 - 04:01 PM EST Learn about SEC filing dates

0001479419false00014794192025-11-102025-11-10

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2025

KALA BIO, Inc.

(Exact Name of Registrant as Specified in its Charter)

​

​	​	​
Delaware	001-38150	27-0604595
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

​

1167 Massachusetts Avenue

Arlington, MA 02476

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 996-5252

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

​

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
​	​
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
​	​
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
​	​
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	KALA	The Nasdaq Capital Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On November 10, 2025, KALA BIO, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5550(b)(2) (the “Minimum MVLS Requirement”) for continued listing on The Nasdaq Capital Market, as the market value of the Company’s listed securities was less than $35 million for the previous 30 consecutive business days. As of the date of this Current Report on Form 8-K, the Company does not meet the alternative standards for continued listing on The Nasdaq Capital Market, as it does not have a stockholders’ equity of at least $2.5 million or net income from continued operations of at least $500,000 in the most recently completed fiscal year or for two of the three most recently completed fiscal years.

In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided a period of 180 calendar days, or until May 11, 2026 (the “Compliance Date”), to regain compliance with the Minimum MVLS Requirement. If, at any time before the Compliance Date, the market value of the Company’s listed securities closes at $35 million or more for a minimum of 10 consecutive business days, the Staff will provide written notification to the Company that it has regained compliance with the Minimum MVLS Requirement.

If the Company does not regain compliance with the Minimum MVLS Requirement by the Compliance Date, the Company will receive written notification that its securities are subject to delisting. At that time, the Company may appeal the Staff’s delisting determination to a Nasdaq Listing Qualifications Panel (the “Panel”) pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by the Staff to the Panel, such appeal would be successful.

The Company intends to monitor the market value of its listed securities and may, if appropriate, consider available options to regain compliance with the Nasdaq Listing Rules.

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	KALA BIO, INC.
​	​	​
Date: November 12, 2025	By:	/s/ Mary Reumuth
​	​	Mary Reumuth
​	​	Chief Financial Officer and Corporate Secretary

​

​

​